CureVac is withdrawing its first-generation Covid-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency. In a statement, the...
German biotech CureVac has canceled manufacturing contracts with two prospective partners for its Covid-19 vaccine CVnCoV while retaining others. The company said on Sept...
CV2Cov, the next-generation Covid-19 vaccine under development by German biotech CureVac and UK drugs giant GSK, outperformed CureVac’s first-generation Covid shot in...
Definitive results from CureVac’s 40,000-subject international Phase 2b/3 trial with its mRNA-based Covid-19 vaccine candidate, CVnCoV, have confirmed an earlier finding...
In a stunning setback to the company’s ambitions of launching its mRNA-based Covid-19 vaccine in the third quarter, results from CureVac’s Phase 2b/3 trial showed the...
German biotech CureVac’s protests against US export restrictions for ingredients it needs to make its Covid-19 vaccine CVnCoV seem to have borne fruit. News agency...
US biotech Novavax has again delayed filing for approval of its protein-based Covid-19 vaccine at least until July this year, citing issues related to an assay needed to...
The European Commission has confirmed rumors that it has initiated legal action against AstraZeneca for failing to meet contractual obligations for deliveries of Its...
